Alnylam Reports Preliminary 2024 Revenue of $1,646 Million and Sets 2025 Guidance
Alnylam said preliminary full-year 2024 global net product revenues were $1,646 million, up 33% from 2023, and fourth-quarter revenues were approximately $451 million. The company also guided to 2025 combined net product revenue of $2,050 million to $2,250 million and expects non-GAAP operating income profitability in 2025, which matters to shareholders because it sets the company's first public outlook for the year. The figures are unaudited and subject to adjustment before full results in February 2025.
Key points
- Preliminary Q4 2024 global net product revenues were approximately $451 million; full-year 2024 was $1,646 million, up 33%.
- 2025 combined net product revenue guidance is $2,050 million to $2,250 million, or 31% growth at the midpoint.
- Total TTR guidance is $1,600 million to $1,725 million; Total Rare guidance is $450 million to $525 million.
- Full results are due in February 2025; the vutrisiran heart-disease PDUFA target action date is March 23, 2025.
The filing
Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.